Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9347766 | 0.98 | CYP2A6 (0.55) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL9347729 | 0.98 | CYP2A6 (0.55) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL3789614 | 0.95 | CYP2A6 (0.58) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL91191 | 0.87 | CYP2A6 (0.62) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL6690187 | 0.84 | DRD2 (0.52) | CYP2A6ALDH1A1CHRNA7SMN1; SMN2CRHBP | |
| SCHEMBL7434783 | 0.82 | CYP2A6 (0.67) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL5540612 | 0.82 | CYP2A6 (0.56) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL17101656 | 0.81 | CYP2A6 (0.62) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL5536097 | 0.81 | CYP2A6 (0.55) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 | |
| SCHEMBL81236 | 0.80 | CYP2A6 (0.58) | CYP2A6IDO1ALDH1A1CHRNA7SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109232523-B | 3-acyl benzothiophene derivative and preparation method thereof | 温州大学 | 2020-06-19 | — | — | CN | disclosed |
| CN-109232523-B | 3-acyl benzothiophene derivative and preparation method thereof | 温州大学 | 2020-06-19 | — | — | CN | disclosed |
| CN-109232523-B | 3-acyl benzothiophene derivative and preparation method thereof | 温州大学 | 2020-06-19 | — | — | CN | disclosed |
| US-9592237-B2 | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2017-03-14 | — | — | US | disclosed |
| US-20160106752-A1 | Use of CB1 Antagonists and/or Inverse Agonists for the Preparation of Drugs that Increase Motor Neuron Excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2016-04-21 | — | — | US | disclosed |
| US-9238027-B2 | Use of CB1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability | FUNDACION DEL HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION (FUHNPAIIN) (ES) | 2016-01-19 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2305220-B1 | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases | INST NAT SANTÉ ET DE LA RECH MÉDICALE INSERM (FR) | 2014-07-30 | — | — | EP | disclosed |
| US-8604060-B2 | Use of antagonists of the CBI receptor for the manufacture of a composition useful for the treatment of hepatic diseases | INSERM (FR) | 2013-12-10 | — | — | US | disclosed |
| US-20120329833-A1 | USE OF ANTAGONISTS OF THE CBI RECEPTOR FOR THE MANUFACTURE OF A COMPOSITION USEFUL FOR THE TREATMENT OF HEPATIC DISEASES | SANOFI-AVENTIS (FR) | 2012-12-27 | — | — | US | disclosed |
| EP-0838461-A2 | Substituted 2,3-aryl-benzothiophene compounds having estrogenic activity | ELI LILLY AND COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0838461-A2 | Substituted 2,3-aryl-benzothiophene compounds having estrogenic activity | ELI LILLY AND COMPANY (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0766559-A4 | CANNABINOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0766559-A4 | CANNABINOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0766559-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-04-09 | — | — | EP | disclosed |
| EP-0766559-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5596106-A | ARYL-BENZO(B)THIOPHENE OR BENZO(B)FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| US-5596106-A | ARYL-BENZO(B)THIOPHENE OR BENZO(B)FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-01-21 | — | — | US | disclosed |
| WO-1996002248-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
| WO-1996002248-A1 | CANNABINOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329833-A1 | USE OF ANTAGONISTS OF THE CBI RECEPTOR FOR THE MANUFACTURE OF A COMPOSITION USEFUL FOR THE TREATMENT OF HEPATIC DISEASES | CNR1, CNR2, GPR55 | CYP2A6 459/4885IDO1 1487/4885ALDH1A1 1996/4885 |
| US-20160106752-A1 | Use of CB1 Antagonists and/or Inverse Agonists for the Preparation of Drugs that Increase Motor Neuron Excitability | CNR1, CNR2, CHRNA9 | CYP2A6 1504/4885IDO1 3996/4885ALDH1A1 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.